Exploring the potential of bacteriophages: How viruses could help fight antibiotic resistance
In a world where the threat of antibiotic-resistant bacteria looms large, a growing number of scientists are turning to a surprising ally in the fight against superbugs—viruses. But not the kind that cause illness in humans. These are bacteriophages, or simply “phages,” viruses that specifically infect and destroy bacteria. Once sidelined by the success of antibiotics, phage therapy is now being re-evaluated as a promising alternative as the medical community grapples with drug resistance.
The concept of using viruses to treat bacterial infections may seem unconventional, but it’s rooted in science dating back over a century. Phages were first discovered independently by British bacteriologist Frederick Twort and French-Canadian microbiologist Félix d’Hérelle in the early 20th century. While the idea took hold in parts of Eastern Europe and the former Soviet Union, the advent of antibiotics in the 1940s pushed phage research to the margins in Western medicine.
Ahora, con la resistencia a los antibióticos transformándose en una crisis de salud mundial, el interés en los fagos está resurgiendo. Cada año, más de un millón de personas en todo el mundo fallecen a causa de infecciones que ya no responden a los tratamientos habituales. Si esta tendencia persiste, esa cifra podría ascender a 10 millones al año para 2050, poniendo en riesgo muchos aspectos del cuidado médico moderno, desde cirugías comunes hasta terapias contra el cáncer.
Phages provide a distinct answer. In contrast to broad-spectrum antibiotics, which eliminate both harmful and beneficial bacteria without distinction, phages exhibit high specificity. They attack particular bacterial strains, leaving nearby microorganisms unaffected. This accuracy not only minimizes unintended harm to the body’s microbiome but also aids in maintaining the long-term efficacy of treatments.
One of the most thrilling elements of phage therapy is how flexible it is. Phages replicate within the bacteria they invade, increasing in number as they eliminate their hosts. This allows them to keep functioning and adapting as they move through an infection. They can be provided in different forms—applied directly to injuries, inhaled for treating respiratory infections, or even employed to address urinary tract infections.
Research labs across the world are now exploring the therapeutic potential of phages, and some are inviting public participation. At the University of Southampton, scientists involved in the Phage Collection Project are working to identify new strains by collecting samples from everyday environments. Their mission: to find naturally occurring phages capable of combating hard-to-treat bacterial infections.
The process of discovering effective phages is both surprisingly straightforward and scientifically rigorous. Volunteers collect samples from places like ponds, compost bins, and even unflushed toilets—anywhere bacteria thrive. These samples are filtered, prepared, and then exposed to bacterial cultures from real patients. If a phage in the sample kills the bacteria, it’s a potential candidate for future therapy.
What makes this approach so promising is its specificity. For example, a phage found in a home environment might be capable of eliminating a strain of bacteria that is resistant to multiple antibiotics. Scientists analyze these interactions using advanced techniques such as electron microscopy, which helps them visualize the phages and understand their structure.
Under a microscope, phages appear nearly extraterrestrial. Their form is similar to that of a spacecraft: a head packed with genetic content, thin legs for clinging, and a tail designed to inject their DNA into a bacterial cell. Once within, the phage overtakes the bacterium’s operations to reproduce, eventually leading to the destruction of the host.
But the journey from discovery to treatment is complex. Each phage must be matched to a specific bacterial strain, which takes time and testing. Unlike antibiotics, which are mass-produced and broadly applicable, phage therapy is often tailored to the individual patient, making regulation and approval more intricate.
Despite these challenges, regulatory bodies are beginning to support the development of phage-based treatments. In the UK, phage therapy is now permitted on compassionate grounds for patients who have exhausted conventional options. The Medicines and Healthcare products Regulatory Agency has also released formal guidelines for phage development, signaling a shift toward greater acceptance.
Experts in the field stress the importance of continued investment in phage research. Dr. Franklin Nobrega and Prof. Paul Elkington from the University of Southampton emphasize that phage therapy could provide vital support in the face of increasing antibiotic resistance. They highlight cases where patients have been left with no effective treatments, underscoring the urgency of finding viable alternatives.
Clinical trials are still necessary to thoroughly confirm the safety and effectiveness of phage therapy, yet optimism is rising. Initial findings are promising, as some experimental therapies have successfully eliminated infections that had previously resisted all standard antibiotics.
Beyond its potential medical applications, phage therapy also offers a new model of public engagement in science. Projects like the Phage Collection Project invite people to contribute to research by collecting environmental samples, providing a sense of involvement in tackling one of the most pressing challenges of our time.
This grassroots approach could be pivotal in uncovering new phages that hold the key to future treatments. As the world confronts the growing threat of antibiotic resistance, these microscopic viruses may prove to be unlikely heroes—transforming from obscure biological curiosities into essential tools of modern medicine.
Looking ahead, the hope is that phage therapy could become a routine part of the medical toolkit. Infections that today pose a serious risk might one day be treated with precision-matched phages, administered quickly and safely, without the unintended consequences associated with traditional antibiotics.
The path forward will require coordinated efforts across research, regulation, and public health. But with the tools of molecular biology and the enthusiasm of the scientific community, the potential for phage therapy to revolutionize infection treatment is real. What was once an overlooked scientific idea may soon be at the forefront of the battle against drug-resistant disease.
